Systematic Review of Chinese Herbal Medicines for Preventing in-Stent Coronary Restenosis after Percutaneous Coronary Intervention

الملخص EN

Percutaneous coronary intervention (PCI) with stent placement is a standard treatment for coronary artery disease (CAD).

In-stent restenosis after PCI remains a challenging clinical problem.

In China, Chinese herbal medicines (CHMs) are widely used for preventing restenosis.

This paper systematically reviewed the literature on the effectiveness and safety of CHMs in preventing restenosis after PCI in patients with CAD.

Electronic databases were searched for randomized controlled trials that compared CHMs plus RWM with the same RWM plus placebo in preventing restenosis after PCI.

A total of 52 trials (4905 patients) on 34 CHMs met the inclusion criteria and were analyzed.

Ten trials had low risk of bias.

Methodological quality of included trials was generally poor.

Meta-analysis showed that at the end of at least 3 months’ followup, CHMs plus RWM could significantly reduce restenosis rate, cardiac mortality, recurrence rate of angina, acute myocardial infarction, numbers of repeat PCI, and numbers of coronary artery bypass graft.

Reported adverse events included gastrointestinal upset, granulocytopenia, and increased alanine transaminase (ALT).

CHMs may help prevent restenosis, thus reducing cardiac mortality after PCI.

Caution should be exercised in drawing a definitive conclusion due to the poor methodological quality of the trials reviewed.